Vanessa Research will start its Phase 2 clinical trials in the first quarter of 2018 for the rare disease Microvillus Inclusion Disease (MVID).

The primary objective of the Phase 2 clinical trials is to test the clinical activity and efficacy of Shylicine™ for the treatment of diarrhea in MVID. In addition, Vanessa expects to verify the reduction in patient dependency on TPN and register changes in intestinal morphology.